Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Long John who wrote (88643)	3/15/2000 6:41:00 PM
From: Bouf	Respond to of 120523

What a percentage move on PSI today MASSIVE!!! :) Wait to Thursday now that news is out!

To: Long John who wrote (88643)	3/16/2000 12:24:00 AM
From: blackmerlin	Respond to of 120523

CYTO: "Beck on Biotech" highly recommends CYTO in newsletter covered by the wire services tonight (see below). Look for a good move back into the upside tomorrow. Regards, Jake Blackmerlin "Beck on Biotech Announces Investment Opinion on "Biotechnology Industry Fundamentally Strong, Sector Decline Due to Confusion" CHICAGO, Mar 15, 2000 (BUSINESS WIRE) -- According to Michael Becker, Editor of the Beck On Biotech Newsletter Confusion over remarks made by President Clinton and British Prime Minister Tony Blair caused many biotechnology and genomics stocks, such as Celera Genomics (NYSE: CRA ), Curagen (NASDAQ: CRGN ) and Affymetrix (NASDAQ: AFFX ), to post sharp declines in yesterday's trading session. Since 1986, the federally funded Human Genome Project has spent over $2 billion to sequence the human genome. Celera Genomics, a private effort, has made tremendous progress in accomplishing this same goal faster and at a much lower cost. Naturally, while there could be some synergy between the public and private efforts to sequence the human genome, private efforts are required to answer to shareholders. The balance between serving human kind and the need for private companies to protect their discoveries has created a political debate in the marketplace. However, as discussed in the February issue of the Beck On Biotech newsletter, sequencing the human genome is not the only task necessary to produce a plethora of new disease treatments and diagnostics. "While genes dictate biological functions, such as the creation of a heart cell as opposed to a liver cell, they do not perform these functions directly." said newsletter editor Michael Becker. In actuality, these genes manufacture numerous proteins that interact with each other via a complex network of biochemical reactions in order to carry out the gene's instructions. Mapping all of the various proteins and their interactions is a field known as proteomics. It is the absences of specific proteins or misfires in the pathway signaling between proteins that are the underlying cause of many diseases. "While sequencing the human genome is an ambitious goal, only by understanding the complex web of protein interactions will the much heralded "new era" of drug treatments and diagnostics come to fruition." said Becker. Leading proteomic companies mentioned in the February issue of Beck On Biotech include: Cytogen Corp (NASDAQ: CYTO ), Curagen (NASDAQ: CRGN ) and Myriad Genetics (NASDAQ: MYGN ). Beck On Biotech is a monthly newsletter that enumerates many different aspects of the biotechnology/pharmaceutical sector. Many issues feature a "company spotlight" that details individual companies who offer unique value or technology. Recently spotlighted companies include Monsanto (NYSE: MTC ), Amylin Pharmaceuticals (NASDAQ: AMLN ) and Dura Pharmaceuticals (NASDAQ: DURA ). For information on how to receive "Beck On Biotech" monthly, contact Michael Becker at 312/431-1700, or via email at editor@beckonbiotech.com . In addition, visit the web site for sample issues and further information: beckonbiotech.com Disclaimers - All comments and opinions are solely those of Michael Becker and are not in any way comments or opinions of Wayne Hummer Investments LLC. Additional information is available upon request. Information in this publication has been obtained from sources believed to be reliable, but the accuracy, completeness and interpretation are not guaranteed. Opinions expressed are subject to change without notice. The opinions and information presented do not constitute a solicitation for the purchase or sale of any securities or options on securities. The security portfolio of the editor of this newsletter, our employees, principals or affiliated companies may, in some instances, include securities and/or options on securities mentioned in each issue. Distributed via COMTEX."